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Abstract:	Neural	crest	cells	arise	in	the	embryo	from	the	neural	plate	border	and	migrate	throughout	the	
body,	giving	rise	 to	many	different	 tissue	types	such	as	bones	and	cartilage	of	 the	 face,	smooth	muscles,	
neurons	 and	 melanocytes.	 While	 studied	 extensively	 in	 animal	 models,	 neural	 crest	 development	 and	
disease	 have	 been	 poorly	 described	 in	 human	 due	 to	 the	 challenges	 in	 accessing	 embryonic	 tissues.	 In	
recent	 years,	 patient-derived	 human	 induced	 pluripotent	 stem	 cells	 (hiPSCs)	 have	 become	 easier	 to	
generate,	 and	 several	 streamlined	 protocols	 have	 enabled	 robust	 differentiation	 of	 hiPSCs	 to	 the	 neural	
crest	lineage.	Thus,	a	unique	opportunity	is	offered	for	modelling	neurocristopathies	using	patient	specific	
stem	 cell	 lines.	 In	 this	work,	we	make	 use	 of	 hiPSCs	 derived	 from	 patients	 affected	 by	 the	 Bardet-Biedl	
Syndrome	(BBS)	ciliopathy.	BBS	patients	often	exhibit	subclinical	craniofacial	dysmorphisms	that	are	likely	
to	be	associated	with	the	neural	crest-derived	facial	skeleton.	We	focus	on	hiPSCs	carrying	variants	in	the	
BBS10	gene,	which	encodes	a	protein	forming	part	of	a	chaperonin-like	complex	associated	with	the	cilium.	
Here,	we	establish	a	pipeline	 for	profiling	hiPSCs	during	differentiation	 toward	 the	neural	 crest	 stem	cell	
fate.	 This	 can	 be	 used	 to	 characterise	 the	 differentiation	 properties	 of	 the	 neural	 crest-like	 cells.	 Two	
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different	 BBS10	mutant	 lines	 showed	 a	 reduction	 in	 expression	 of	 the	 characteristic	 neural	 crest	 gene	
expression	profile.	 Further	 analysis	 of	 both	BBS10	mutant	 lines	 highlighted	 the	 inability	 of	 these	mutant	
lines	 to	differentiate	 towards	a	neural	 crest	 fate,	which	was	also	 characterised	by	a	decreased	WNT	and	
BMP	 response.	Altogether,	 our	 study	 suggests	 a	 requirement	 for	wild-type	BBS10	 in	human	neural	 crest	
development.	 In	 the	 long	 term,	approaches	 such	as	 the	one	we	describe	will	 allow	direct	 comparison	of	
disease-specific	 cell	 lines.	 This	 will	 provide	 valuable	 insights	 into	 the	 relationships	 between	 genetic	
background	and	heterogeneity	in	cellular	models.	The	possibility	of	integrating	laboratory	data	with	clinical	
phenotypes	will	move	us	towards	precision	medicine	approaches. 
	
Introduction:			
Neural	 crest	 cells	 are	 a	 highly	migratory,	multipotent	 stem	 cell	 population	 that	 contributes	 to	 a	
broad	 range	 of	 tissues,	 including	 craniofacial	 bone	 and	 cartilage,	 peripheral	 neurons,	 glia,	 pigment,	 and	
other	 cells	 during	 embryonic	 development	 (Trainor,	 2014).	 Elucidating	 the	 cellular	 and	 molecular	
mechanisms	of	lineage	specification	and	migration	of	neural	crest	stem	cells	is	essential	for	understanding	
the	pathogenesis	of	neurocristopathies,	a	 family	of	diseases	caused	by	anomalies	 in	 the	migration	or	cell	
behaviour	of	neural	 crest	 cells.	 Ciliopathies	 are	a	 class	of	 genetic	disorders	 characterised	by	mutation	of	
proteins	 affecting	 the	 structure	 or	 function	 of	 the	 cilium	 (Eggenschwiler	 &	 Anderson	 2007;	 Ishikawa	 &	
Marshall	 2011).	 The	 cilium	 is	 a	 microtubule-based	 cellular	 organelle	 crucial	 for	 cell	 signalling,	
mechanotransduction	and	 fluid	 flow,	 such	as	 in	airways	and	brain	ventricles.	 Loss	of	 the	cilium	has	been	
linked	to	craniofacial	anomalies	such	as	micrognathia	and	facial	clefting	(Adel	Al-lami	et	al,	2016;	Cortes	et	
al.,	2015).	Cranial	ciliopathies	are	caused	by	mutations	in	ciliary	genes	that	may	result	from	altered	neural	
crest	cell	development	(Cortes	et	al.,	2015).	How	neural	crest	cell	migration	(see	Tobin	et	al.	2008;	Schock	
et	al.,	2015)	is	affected	by	cilia	defects	remains	to	be	fully	explored.	
Bardet-Biedl	Syndrome	(BBS)	is	a	prototypic	ciliopathy	that	can	affect	neural	crest-derived	tissues.		
BBS	proteins	can	be	categorised	by	their	location	and	function	within	the	primary	cilia,	with	a	subset	of	BBS	
proteins	 forming	 the	 BBSome	 (Figure	 1A).	 The	 BBSome	 is	 an	 adaptor	 complex	 that	 is	 crucial	 for	 cilia	
function	(Suspitsin	&	Imyanitov	2016;	Jin	&	Nachury,	2009).	Clinical	findings	indicate	that	patients	carrying	
BBS	mutations	often	present	with	 subclinical	 craniofacial	 changes	 including	 speech	and	oral	phenotypes,	
mid-facial	 flattening	and	some	mild	retrognathia	(Panny	et	al.	2017;	Tobin	et	al.	2008).	 	 In	addition,	Bbs6	
mutant	mouse	skulls	showed	a	reduction	in	the	size	of	the	pre-maxillary	and	maxillary	regions	(Tobin	et	al.	
2008).	 Similarly,	 zebrafish	 knockdowns	 of	 bbs4,	 bbs6	 and	 bbs8	 had	 shortened	 facial	 cartilages	 and	
mandibles	correlating	with	a	reduction	in	neural	crest	cell	migration	(Tobin	et	al.,	2008).		
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We	focused	on	BBS10	due	to	the	high	prevalence	of	BBS10	mutations	in	humans,	which	comprises	
approximately	20%	of	the	BBS	population	(Stoetzel	et	al.	2006;	Forsythe	&	Beales	2012).	BBS10,	along	with	
BBS6	and	12,	is	part	of	a	chaperonin-like	complex	which	mediates	the	assembly	of	the	BBSome	(Seo	et	al.	
2010;	 Zhang	 et	 al.	 2012;	 Billingsley	 et	 al.	 2010;	 Stoetzel	 et	 al.	 2007;	 Stoetzel	 et	 al.	 2006).	 Phenotypes	
associated	with	BBS6,	10	and	12	are	thought	to	be	more	severe	than	other	commonly	mutated	BBS	genes	
like	BBS1	 (Castro-Sánchez	 et	 al.	 2015).	 Furthermore,	bbs10	morphant	 zebrafish	 larvae	 exhibit	 shortened	
body	axis	and	poor	somitic	definition	among	other	more	variable	phenotypes,	while	a	sub-phenotypic	dose	
of	bbs10	morpholino	oligonucleotides	(MO)	exacerbates	the	phenotypes	observed	in	other	bbs	morphants	
(Stoetzel	 et	 al.	 2006).	 In	 alignment	with	 the	 human	disease,	Bbs10	 knockout	mice	 are	 viable	 but	 exhibit	
obesity,	retinal	degeneration	and	cystic	kidney	phenotypes	(Cognard	et	al.	2015).	
Together,	these	studies	in	fish	and	mouse	suggest	that	BBS10	is	necessary	for	normal	cilia	function,	
and	when	mutated,	causes	a	range	of	BBS	phenotypes.	The	potential	neural	crest	defects	observed	in	the	
knockdowns	 also	 fit	 generally	 with	 observations	 linking	 ciliopathic	 mutations	 and	 craniofacial	
malformations	 in	 humans.	 It	 is	 unclear	what	 specific	 alterations	 in	 neural	 crest	 cell	 (NCC)	 functions	 (e.g	
differentiation,	 migration)	 are	 caused	 by	 mutations	 in	 BBS10.	 To	 define	 the	 pathogenic	 mechanisms	 of	
these	mutations,	we	sought	to	model	NCC	induction	in	BBS10	mutant	iPSCs.		
Human	 induced	 pluripotent	 stem	 cells	 (hiPSC)	 are	 a	 powerful	 tool	 for	 the	 study	 of	 human	
developmental	 disorders	 as	 they	 can	 be	 used	 to	 model	 genotype-specific	 molecular	 and	 cellular	
phenotypes	during	differentiation.	Over	the	last	decade,	several	protocols	have	been	developed	for	neural	
crest	cell	(NCC)	induction	from	hiPSCs,	using	defined	factors	at	specific	time	points	to	generate	‘purer’	cell	
populations	 which	 can	 be	 used	 to	 study	 induction,	 migration	 and	 differentiation	 (Leung	 et	 al.	 2016;	
Menendez	et	al.	2013;	Chambers	et	al.	2013;	reviewed	in	Zhu	et	al.,	2016).	The	Human	Induced	Pluripotent	
Stem	Cell	Initiative	(HipSci,	http://www.hipsci.org)	has	generated	and	characterised	a	panel	of	hundreds	of	
hiPSCs	 including	 from	 a	 significant	 cohort	 of	 Bardet-Biedl	 Syndrome	 (BBS)	 patients	 hosting	 a	 diverse	
spectrum	of	mutations	in	genes	involved	in	BBS.	Here,	as	a	proof	of	concept,	we	use	the	recently	described	
Leung	et	al.,	protocol	to	obtain	efficient	neural	crest	induction	and	compare	HipSci	cell	lines	from	healthy	
volunteers	 with	 two	 cell	 lines	 obtained	 from	 Bardet-Biedl	 Syndrome	 patients	 carrying	 BBS10	mutations	
(Table	1).	We	show	that	both	mutant	BBS	hiPSCs	have	altered	neural	crest	 induction	and	differentiation,	
demonstrating	 the	 feasibility	of	using	hiPSCs	 from	ciliopathies	 to	explore	processes	affecting	neural	crest	
induction.	This	approach	will	help	us	to	define	the	human	phenotypes	and	dissect	the	role	of	cilia	during	
neural	crest	development.	
	
MATERIALS	AND	METHODS:	
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Human	induced	pluripotent	cell	lines	(hiPSC):		
Control	hiPSCs	and	Bardet-Biedl	Syndrome	(BBS)	patient-derived	hiPSC	lines	harbouring	mutations	
in	BBS10,	part	of	the	ciliary	chaperonin	complex	(Figure	1A)	were	obtained	from	the	HipSci	consortium	(see	
Table	 1).	 hiPSCs	 were	 maintained	 in	 Essential	 8	 media	 (ThermoFisher)	 on	 an	 extracellular	 matrix	
replacement,	Matrigel	(Corning).	XIRY	was	initially	obtained	cultured	on	Matrigel	whereas	QOLG	and	LAIG,	
acquired	on	vitronectin,	were	cultured	on	Matrigel	 for	 several	passages	 to	ensure	 that	 all	 cell	 lines	were	
comparable.	 Cells	 were	 typically	 passaged	 twice	 weekly	 using	 0.5mM	 EDTA,	 dissociated	 with	 gentle	
pipetting	and	analysed	between	passages	30-60.		
TABLE	1	
Donor	 Cell	line	 BBS10	variant	1	 BBS10	variant	2	 Age	 Sex	 Ethnicity	
QOLG	 Qolg_1	 Wildtype	 Wildtype	 35-39	 Male	 White,	British	
KEGD	 Kegd_2	 Wildtype	 Wildtype	 40-44	 Male	 White,	British	
XIRY	 Xiry_5	 c.989T>C/p.Val330Ala	 c.235dup/p.Thr79Asnfs*17	 35-39	 Male	 White,	British	
LAIG	 Laig_1	 c.285A>T/p.Arg95Ser	 c.2119_2120del/p.Val707*	 25-29	 Female	 White,	European	
	
Neural	crest	induction:		
Neural	 crest	 induction	 was	 carried	 out	 as	 per	 Leung	 et	 al.	 2016	 (Leung	 et	 al.	 2016),	 which	 is	
designed	to	mimic	normal	neural	crest	development	(Figure	2).	TrypLE	Express	(Thermo	Fisher)	was	used	to	
detach	hiPSCs	into	a	single	cell	suspension.	Next,	200,000	hiPSCs	were	plated	in	each	well	of	a	6-well	plate	
coated	with	Matrigel.	At	 the	 start	 of	 the	 induction	protocol	 (time	=	0	hours),	wells	were	 incubated	with	
neural	 crest	 induction	medium	 +	 10µM	 Y-27632	 (Cell	 Guidance	 Systems)	 for	 the	 first	 48	 hours	 (48h)	 of	
culture,	then	in	neural	crest	induction	media	alone	for	the	 indicated	time.	Samples	were	then	fixed	in	4%	
PFA	in	PBS	for	antibody	staining	or	lysed	in	Trizol	(Sigma)	for	RNA	extraction.	Neural	crest	induction	media	
is	 as	 per	 Leung	 et	 al.,	 2016:	 50:50	 DMEM:F12	 (Sigma),	 2%	 B27	 supplement	 (Life	 Technologies),	 1X	 L-
glutamine	(Invitrogen),	0.5%	BSA	(Sigma),	3µM	CHIR99021	(Sigma).	
Immunofluorescent	Antibody	Staining:	
After	fixation,	cells	were	washed	three	times	in	1X	PBS	and	then	permeabilised	by	incubation	with	
0.5%	TritonX-100	(Sigma)	in	1X	PBS	for	5	minutes	at	room	temperature.	Next,	cells	were	blocked	for	1	hour	
at	room	temperature	(in	3%	BSA	(Sigma)	in	1X	PBS,	0.01%	Tween20	(Sigma)).	Primary	antibodies	(see	table)	
were	incubated	overnight	at	4°C	in	blocking	solution.	Three	15	minute	washes	in	PBS	with	1%	BSA,	0.01%	
Tween	20	were	carried	out.	Fluorescent	secondary	antibodies	were	diluted	in	blocking	solution	and	plates	
were	 incubated	 at	 room	 temperature	 for	 1-2	 hours.	Next,	 three	 15	minute	washes	 in	 PBS	with	 1%	BSA,	
0.01%	Tween	20	were	carried	out.	Hoechst	33342	 (Sigma),	diluted	at	1:1000	 from	a	20mg/ml	 stock,	was	
added	to	the	first	wash	as	a	nuclear	stain.		
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TABLE	2	
Antibody	 Targets:	 Concentration	 Supplier	(catalog	number)	
ARL13B	 Ciliary	axoneme	 1:500	 Proteintech	(17711-1-AP)	
SOX10	 migratory	neural	crest	 1:500	 Santa	Cruz	(sc-365692)	
OCT3/4	 pluripotency	 1:200	 Santa	Cruz	(sc-5279)	
P75NTR	 neurotrophin	
receptor/neural	crest	
1:600	 Millipore	(07-476)	
Anti-mouse	488	 secondary	antibody	 1:500	 Invitrogen	(A11001)	
Anti-rabbit	568	 secondary	antibody	 1:500	 Invitrogen	(A11011)	
Anti-rabbit	488	 secondary	antibody	 1:500	 Invitrogen	(A11008)	
	
Microscopy	and	Imaging:		
Cells	 were	 routinely	 viewed	 and	 imaged	 by	 phase-contrast	microscopy.	 Fluorescence	 imaging	 of	
immunostained	samples	was	carried	out	using	an	inverted	epifluorescence	microscope	(Zeiss	or	Olympus)	
with	a	plate	stage	adaptor.	All	image	processing	was	carried	out	in	Image	J.	Figures	were	made	using	Adobe	
Illustrator	CS5.5.	
	Cilia	 quantification	 was	manually	 carried	 out	 using	 the	 cell	 counter	 plugin	 of	 ImageJ.	 For	 these	
quantifications	the	control	line	KEGD	was	used	due	to	lack	of	QOLG	line	availability.	In	addition,	these	cells	
were	cultured	on	vitronectin	rather	than	Matrigel	(Corning).	The	percentage	of	ciliated	cells	was	calculated	
from	total	nuclei	and	cilia	counts	manually	obtained	from	representative	 images	(total	number	of	control	
cells	counted:	KEGD=2631,	mutant	cells:	LAIG=2293	and	XIRY=1742).	Nuclei	and	cilia	of	cells	touching	the	
field	edge	were	assessed	from	contrast	adjustment	of	the	ARL13B	channel	and	excluded.	
Quantitative	reverse	transcription	polymerase	chain	reaction	(qRT-PCR):		
RNA	was	extracted	from	hiPSCs,	after	48hr	of	induction	or	120hr	of	induction,	using	Trizol	(Sigma)	
as	 per	manufacturer’s	 instructions.	 RNA	was	 then	DNAse	 I	 (Promega)	 treated.	 500	 ng	 to	 1	µg	 of	DNAse	
treated	 RNA	 was	 primed	 with	 random	 hexamers	 (Promega)	 and	 reverse	 transcription	 was	 carried	 out	
according	to	manufacturer’s	protocol	(M-MLV	Reverse	Transcriptase,	Promega,	M1701.	All	qRT-PCRs	were	
performed	using	Bioline	2X	Sensimix	(QT605-05)	using	a	Roche	Lightcycler	480.	Quantification	of	each	PCR	
reaction	was	carried	out	using	absolute	standards,	and	normalised	to	β-actin	levels.	Statistical	significance	
for	all	RT-qPCR	data	was	analysed	using	un-paired,	Student’s	T	tests.	
TABLE	3	
Gene	 Forward	Primer		 Reverse	Primer		
β -ACTIN AGCCTCGCCTTTGCCG	 CTCGTCGCCCACATAGGAAT	
CMYC	 TTTCTGAAGAGGACTTGTTGCGGAAACGAC	 TCAGCCAAGGTTGTGAGGTTGCATTTGATC	
NANOG	 TCTCTCCTCTTCCTTCCTCCATG	 CTGTTTGTAGCTGAGGTTCAGGATG	
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OCT3/4	 GACAGGGGGAGGGGAGGAGCTAGG	 CTTCCCTCCAACCAGTTGCCCCAAAC	
BRY	 TATGAGCCTCGAATCCACATAGT	 CCTCGTTCTGATAAGCAGTCAC	
AXIN2	 AGTCAGCAGAGGGACAGGAA	 AGCTCTGAGCCTTCAGCATC	
PTC1	 CCCCTGTACGAAGTGGACACTCTC	 AAGGAAGATCACCACTACCTTGGCT	
SIX1	 TCAGCTCCAAGACTCTCTGC	 ACAAGCTGCAAAAATGTTCC	
SOX2	 TCAAGCGGCCCATGAATGCC	 AGCCGCTTAGCCTCGTCGAT	
TFAP2A	 GATCCTCGCAGGGACTACAG	 TACCCGGGTCTTCTACATGC	
ZIC1	 GTCCTACACGCATCCCAGTT	 GCGATAAGGAGCTTGTGGTC	
MSX1	 CTGCACCCTCCGCAAACACA	 AGGCTGAGCGAGCTGGAGAA	
PAX3	 AATTACTCAAGGACGCGGTC	 TTCTTCTCGCTTTCCTCTGC	
PAX7	 TGACAGCTTCATGAATCCGG	 GATGGAGAAGTCAGCCTGTG	
FOXD3	 GCATCTGCGAGTTCATCAGC	 CGTTGAGTGAGAGGTTGTGG	
SOX10	 CTCTGGAGGCTGCTGAA	 TGGGCTGGTACTTGTAGTC	
SNAI2	 CAGACCCTGGTTGCTTCAAG	 GAGCCCTCAGATTTGACCTG	
	
RESULTS:	
Comparable	culture	conditions	for	pluripotent	stem	cells	
We	 selected	 several	 lines	 from	 the	HipSci	 cell	 bank:	 a	 control	 line,	 KEGD	 (cilia	 quantitation)	 and	
QOLG	(used	for	the	majority	of	our	assays)	and	two	BBS10	mutant	lines,	XIRY	and	LAIG.	Both	mutant	lines	
carry	 compound	heterozygous	 variants	 (Figure	 1B	 and	 Table	 1).	 The	 XIRY	 line	 carries	 two	 alleles:	 a	 non-
synonymous	change	(V330A)	on	one	allele,	and	a	duplication	on	the	other	allele	that	leads	to	a	frameshift	
and	an	early	stop	(T79Nfs*17),	likely	to	result	in	a	loss-of-function	variant	(Figure	1B).	LAIG	carries	an	allele	
with	a	synonymous	mutation	(R95S)	and	an	allele	with	a	2-base	pair	deletion	leading	to	a	truncated	protein	
lacking	 the	 final	16	amino	acids	 (V707*)	 (Figure	1B).	Based	on	 these	genotypes,	we	expect	 that	 the	XIRY	
variants	 will	 have	 a	 more	 significant	 impact	 on	 protein	 function.	Matrigel	 was	 used	 to	 wean	 lines	 for	
comparable	results	and	all	cell	lines	exhibited	an	embryonic	stem	(ES)	cell-like	state,	forming	tight	colonies	
of	packed	cells	 (Figure	1C-E).	Cultures	were	discarded	 if	delaminating,	 if	differentiated	cells	were	present	
on	 greater	 than	 25%	 of	 the	 colonies,	 or	 if	 large	 regions	 of	 non-colony	 bound	 cells	 were	 present.	 We	
confirmed	 that	our	 culture	 conditions	were	 suitable	 for	maintaining	pluripotency	 in	all	 three	hiPSC	 lines.	
Immunostaining	for	OCT3/4,	one	of	the	defining	features	of	pluripotency,	was	carried	out	on	all	three	lines	
after	 adaptation	 to	 Matrigel.	 All	 lines	 exhibited	 positive	 nuclear	 staining	 for	 OCT3/4	 confirming	 the	
pluripotent	nature	of	these	cells,	and	no	significant	differences	were	observed	in	BBS10	mutants	compared	
to	controls	(Figure	1C-E).	
	
Reduced	primary	cilia	expression	in	BBS10	mutant	hiPSCs	
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Normally,	a	proportion	of	cells	within	hiPSC	colonies	express	primary	cilia	 (Nathwani	et	al.	2014).	
To	confirm	that	BBS10	mutant	cells	are	still	able	 to	generate	cilia,	we	performed	 immunostaining	on	 the	
hiPSCs	 with	 ARL13B,	 a	 marker	 of	 the	 ciliary	 axoneme.	 We	 found	 that	 both	 control	 lines	 expressed	 an	
abundance	of	cilia-specific	ARL13B	staining	(KEGD,	shown	in	Figure	1F;	QOLG,	data	not	shown).	Both	BBS10	
mutant	 lines	 also	 had	 cells	 with	 positive	 staining	 (Figure	 1G-H).	 Both	 mutant	 lines	 expressed	 cilia;	
interestingly,	 quantification	 indicated	 that	 LAIG	 and	 not	 XIRY	 had	 a	 slight	 but	 statistically	 significant	
increase	in	the	number	of	cilia	numbers	compared	to	control	(Figure	1F-I).	Anecdotally,	the	percentage	of	
cells	with	cilia	in	XIRY	was	very	variable	(Figure	1G,	I).	These	data	suggest	that	BBS10	is	not	strictly	required	
for	ciliogenesis,	at	least	in	the	pluripotent	state.	
	
Differentiation	of	hiPSCs	to	neural	crest	stem	cells	
To	 confirm	 that	 both	normal	 and	BBS10	mutant	 hiPSCs	 could	be	differentiated	 towards	 the	neural	 crest	
lineage,	 we	 used	 a	 5-day	 induction	 protocol	 where	 activation	 of	 the	 WNT	 pathway	 (via	 inhibition	 of	
glycogen	 synthase	 kinase-3	 (GSK-3))	 induces	 neural	 border	 genes	 and	 neural	 crest	 markers	 mimicking	
normal	neural	crest	development	(Figure	2)	(Leung	et	al.,	2016).	Cells	were	monitored	daily	and	unattached	
cells	were	washed	away	during	media	changes,	leaving	behind	adherent	colonies.	At	initial	plating,	control	
and	mutant	cells	formed	small	colonies	with	protrusions	(Figure	3A,	F,	K).	By	48h	of	culture,	a	subset	of	cells	
in	the	control	QOLG	colonies	have	begun	delaminating	(Figure	3C,	blue	arrowhead).	This	was	rarely	seen	in	
BBS10	mutant	colonies	at	48	hours	(Figure	3H,	3M).	In	contrast,	mutant	cell	colonies	showed	delamination	
at	 96	 hours	 of	 culture	 (Figure	 3J,	 3N,	 blue	 arrowheads).	 These	 results	 suggest	 a	 delay	 in	 neural	 crest	
induction	in	BBS10	mutants. 
Furthermore,	despite	being	 initially	plated	at	 the	 same	density,	 fewer	cells	were	observed	 in	 the	
mutant	 cultures	 over	 the	 first	 72h	 of	 culture.	 By	 day	 5,	most	 areas	 of	 cultures	 had	 reached	 confluency;	
however,	the	control	was	visibly	denser	(Figure	3E).	At	120h	dense	areas	(yellow	arrowheads,	Figure	3E,	J,	
O)	were	present,	and	these	resembled	the	morphology	of	colony-like	arrangements	seen	throughout	 the	
cultures.	Upon	close	inspection	of	the	delaminating	stage	of	QOLG	and	XIRY	cells	(48h-96h,	Figure	4),	it	was	
noted	that	XIRY	cells	showed	fewer	protrusions	from	the	colonies	of	cells	at	48h	and	72h	timepoints	(Figure	
4,	D	and	E).	At	96h	mutant	cells	are	seen	delaminated	from	cell	colonies	(Figure	4,	F).	These	data	indicate	
that	some	neural	crest	induction	is	taking	place,	with	cells	delaminating	from	control	colonies	earlier	than	
mutants.	
	
Decreased	expression	of	neural	crest	markers	in	mutant	cells	
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During	embryogenesis,	the	transcription	factor	SOX10	and	the	p75	neurotrophin	receptor	(p75NTR)	
are	expressed	 in	migratory	neural	 crest	 cells.	 In	order	 to	determine	 the	 identity	of	 the	 induced	cells,	we	
carried	out	immunostaining	for	these	markers.	By	5	days	of	differentiation	a	majority	of	cells	showed	some	
level	of	SOX10	expression	(Figure	5).	The	QOLG	control	line	showed	much	higher	levels	of	SOX10	and	p75NTR	
expression	compared	to	the	mutant	lines	(Figure	5A-C).	Consistent	with	SOX10	association	with	migratory	
neural	crest	cells,	cells	that	most	strongly	expressed	SOX10	were	delaminated	cells	at	the	edge	of	colonies	
(Figure	5A).	We	also	found	cells	co-expressing	p75NTR	and	SOX10	around	the	periphery	of	control	colonies	
(Figure	5A-A”).	In	contrast,	both	mutant	cultures	had	markedly	diminished	expression	of	SOX10	and	almost	
no	evidence	of	 p75NTR	expression	 (Figure	5B-C”),	 although	 levels	 of	 SOX10	were	 still	 above	background	
(compare	Figure	5D	to	5B-C).		
	
Gene	expression	analysis	during	induction	of	the	neural	crest	lineage		
As	noted	above,	the	neural	crest	protocol	is	designed	to	first	induce	a	neural	border	state,	which	is	
necessary	 for	 subsequent	 neural	 crest	 induction.	 In	 order	 to	 determine	 the	 steps	 at	 which	 neural	 crest	
induction	might	be	perturbed,	we	examined	gene	expression	profiles	over	the	120h	protocol.	We	harvested	
mRNA	for	quantitative	RT-PCR	analysis	at	0h,	where	cells	should	be	self-renewing	hiPSCs,	at	48h	induction,	
at	the	onset	of	neural	border	formation,	and	at	120h,	when	cells	should	be	expressing	neural	crest	markers.	
Specifically,	we	 tested	 the	control	 line	QOLG	and	 the	mutant	 line	XIRY,	as	 these	 lines	were	derived	 from	
age/gender	matched	donors.		
	 To	 confirm	 the	 exit	 from	 pluripotency,	 we	 first	 analysed	 the	 expression	 of	 CMYC,	 NANOG	 and	
OCT3/4,	 which	 should	 become	 progressively	 reduced	 during	 the	 120h	 period.	 Indeed,	 these	 markers	
diminished	as	predicted	in	both	QOLG	and	XIRY;	however,	it	is	worth	noting	that	XIRY	cultures	exhibited	a	
significantly	higher	level	of	all	three	pluripotency	markers	at	the	outset,	including	surprisingly	higher	levels	
of	NANOG	and	OCT3/4	at	48h	(Figure	6A-C).	 Interestingly,	LAIG	also	expressed	higher	 levels	of	OCT3/4	at	
the	 iPSC	 period	 but	 not	 NANOG	 or	 CMYC	 (Figure	 6C).	 By	 120h	 of	 culture,	 both	 lines	 had	 almost	 no	
expression	 of	 pluripotency	 markers.	 Nevertheless,	 the	 delayed	 loss	 of	 pluripotency	 markers	 could	 be	
indicative	of	a	failure	to	respond	to	signals	that	induce	the	neural	plate	border.	
	 We	 then	 examined	 expression	 of	 neural	 plate	 border	 markers,	 including	 PAX3,	 PAX7,	 TFAP2A	
(Figure	 6D-F).	As	expected,	 the	 control	 line	 showed	an	 increase	 in	 all	 three	neural	 plate	border	markers	
over	time,	with	steadily	increasing	levels	at	48h	and	120h.	In	contrast,	while	there	was	some	increase	in	all	
three	markers	at	48h	 in	XIRY	compared	to	the	start	of	the	 induction,	neither	PAX3	nor	PAX7	 reached	the	
higher	 levels	 achieved	 in	 QOLG	 at	 120h	 (Figure	 6D-F).	 LAIG	 also	 fails	 to	 upregulate	 neural	 plate	 border	
markers	PAX3	and	TFAP2A	(Figure	6D-E).	For	technical	reasons,	we	were	unable	to	assess	PAX7	expression	
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in	LAIG.	Together,	this	demonstrates	that	induction	of	the	neural	plate	border	genes	is	not	delayed,	and	is	
instead	unable	to	reach	the	levels	attained	in	controls.	Altogether	these	results	are	strongly	indicative	of	a	
failure	to	respond	appropriately	to	inductive	signals.	
	 When	we	examined	expression	of	the	neural	crest	markers	FOXD3,	SOX10	and	SNAIL2	by	qPCR,	we	
found	a	profile	similar	to	that	of	the	neural	border	markers.	While	there	was	induction	of	all	three	genes	
during	 the	 differentiation	 protocol,	 expression	 levels	 in	 both	 mutant	 cell	 lines	 were	 significantly	 lower	
compared	 to	control	 (Figure	6G-I).	 It	 is	worth	noting	 that	prior	 to	neural	 crest	 induction,	 LAIG	expressed	
significantly	higher	 levels	of	FOXD3	 (Figure	6G),	which	was	 lost	by	48	hours	of	 induction.	 This	 raised	 the	
possibility	that	the	mutant	cell	lines	responded	to	the	differentiation	protocol	via	induction	of	a	non-neural	
crest	state.	Note	that	we	see	some	moderate	induction	of	neural	border	and	neural	crest	markers	in	XIRY.	
Surprisingly,	we	 found	 that	 XIRY	 expressed	 significantly	 higher	 levels	 of	 the	mesodermal	marker	
Brachyury	(BRY)	by	2	days	of	culture	(Figure	7A).	SOX2	expression	is	an	early	marker	of	pluripotency	(during	
the	 hiPSC	 stage)	 and	 then	 becomes	 a	marker	 of	 neural	 tissues.	 Consistent	with	 this,	 control	 QOLG	 cells	
express	SOX2	initially	(0	hrs),	followed	by	a	peak	at	neural	border	stages	(48	hours)	and	a	dip	as	neural	crest	
induction	 progresses.	 In	 contrast,	 we	 found	 that	 XIRY	 cells	 had	 normal	 levels	 of	 SOX2	 initially,	 but	 this	
decreased	significantly	by	day	5	of	culture	(Figure	7B).	SOX2	expression	in	the	mutant	LAIG	was	significantly	
lower	during	pluripotency	stages,	but	responded	normally	to	induction.		
We	 next	 examined	 two	markers	 of	 the	 pre-placodal	 ectoderm	 (PPE).	 Similar	 to	 the	 neural	 crest	
lineage,	 the	 pre-placodal	 ectoderm	 also	 relies	 on	 the	 appropriate	 induction	 of	 the	 neural	 border.	 ZIC1	
marks	both	the	neural	border	and	subsequently	the	PPE,	and	in	controls,	can	be	seen	increasing	over	the	
course	of	the	5-day	protocol	(Figure	7C).	To	our	surprise,	ZIC1	is	significantly	higher	in	XIRY	mutant	cells	at	
48	hours	but	this	trend	is	not	continued,	and	levels	of	ZIC1	in	the	mutant	are	significantly	lower	by	5	days	of	
culture	 (Figure	 7C).	 At	 all	 stages	 throughout	 induction,	 expression	 of	 ZIC1	was	 significantly	 reduced	 in	
mutant	LAIG.	Sustained	ZIC1	expression	is	necessary	for	activation	of	pre-placodal	ectoderm	genes	such	as	
SIX1	 (Hong	&	 Saint-Jeannet	 2007);	 consistent	with	 this,	 in	 XIRY,	 there	 is	 only	 a	minimal	 increase	 of	SIX1	
expression	at	5	days	compared	to	controls	(Figure	7D).	For	technical	reasons,	we	were	unable	to	compare	
SIX1	levels	in	LAIG.	
Given	the	importance	of	BMP	and	WNT	signals	during	specification	of	the	neural	plate	border	and	
subsequently	in	induction	of	the	neural	crest	and	pre-placodal	lineages,	we	hypothesized	that	the	mutant	
line	 had	 a	 dampened	 response	 to	 these	 key	 signals.	 To	 test	 this,	 we	 examined	 expression	 of	 the	Wnt-
responsive	 gene	Axin2	 and	 the	BMP-responsive	 gene	MSX1	 (Figure	 7E,	 7F,	 respectively).	 Consistent	with	
reports	 from	Leung	et	al.,	 (2016)	we	saw	a	graded	 increase	 in	AXIN2	expression	 in	the	control	 line	QOLG	
during	induction	(Figure	7E).	Both	mutant	lines	showed	drastically	lower	expression	of	AXIN2	by	5	days	of	
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culture	(Figure	7E).	Similarly,	the	BMP-responsive	gene	MSX1	failed	to	be	up-regulated	in	the	mutant	lines	
(Figure	7F).	Due	 to	 the	 crucial	 role	 for	 cilia	 in	Hedgehog	 (Hh)	 signalling,	we	also	examined	 the	Hh	 target	
Patched1	(PTC1).	There	was	generally	no	significant	difference	between	control	and	mutant	lines;	however,	
mutants	did	show	some	variable	increase	early	in	induction	(Figure	7G).	This	could	indicate	a	lack	of	ciliary-
mediated	 processing	 of	 the	 GLI	 repressors.	 Taken	 together,	 these	 data	 suggest	 that	 a	 failure	 in	 signal	
responsiveness	in	mutant	cells	underlies	the	observed	neural	crest	induction	phenotype.		
	
DISCUSSION	
Neurocristopathies,	 or	 diseases	 of	 the	 neural	 crest	 lineage,	 were	 first	 considered	 collectively	 by	
Bolande	(Bolande	1974).	Since	then,	it	has	become	clear	that	these	disorders	encompass	a	broad	variety	of	
diseases	(Vega-Lopez	et	al.	2018).	Due	to	the	diversity	of	neural	crest	derivatives,	mutations	affecting	this	
lineage	lead	to	many	pleiotropic	phenotypes.	Furthermore,	the	assimilation	of	the	neural	crest	lineage	into	
multiple	organ	systems	makes	 it	particularly	difficult	 to	assess	 function	of	this	 lineage	 in	vitro.	Therefore,	
recent	 advances	 in	 human-derived	 cellular	 approaches	 offer	 new	 tools	 for	 the	 study	 of	 complex	 human	
conditions.	 To	 be	 able	 to	 best	 use	 these	 patient-derived	 cells,	 there	 is	 an	 acute	 need	 to	 establish	
streamlined,	 robust	and	reproducible	assays	to	test	each	step	of	neural	crest	 formation.	 In	 this	work,	we	
used	 the	 short	 neural	 crest	 induction	 protocol	 developed	 by	 Leung	 and	 colleagues	 to	 determine	 key	
requirements	for	a	disease	gene	in	neural	crest	stem	cell	pathology	(Leung	et	al.,	2016).		
The	 long-term	goal	of	 a	project	 such	as	 this	 is	 the	ability	 to	model	 “disease	 in	a	dish”,	using	 the	
patient’s	own	cells	 to	understand	 the	underlying	cellular	and	molecular	causes	of	pathology	or	using	 the	
patient’s	cells	to	design	new	therapeutics.	This	approach	complements	existing	animal	models,	which	are	
very	powerful	for	in	vivo	studies,	but	often	do	not	entirely	recapitulate	the	human	condition.	For	example,	
genetic	 knock-outs	 of	 crucial	 genes	 frequently	 lead	 to	 embryonic	 lethality.	 However,	 it	 is	 clear	 from	
disorders	such	as	BBS,	that	the	human	disease	variants	are	often	of	unknown	function	and	difficult	to	study	
without	 a	 clear	 cellular	 or	molecular	 assay.	 Furthermore,	 genes	 such	 as	BBS10	 lead	 to	 a	 broad	 range	 of	
phenotypes	 in	 patients,	 including	 different	 manifestations	 from	 sibling	 to	 sibling	 (carrying	 the	 same	
variant).	This	variability	also	complicates	our	understanding	of	gene-function	interactions.	
To	truly	link	gene	identity	to	gene	function	using	animal	models,	it	would	be	necessary	to	generate	
“humanised”	models:	 e.g.,	 knock-ins	 of	 human	disease	 gene	 variants.	 This	 is	 clearly	 not	 feasible	 in	most	
cases,	and,	may	not	truly	reflect	the	human	condition	due	to	genetic	background.	While	use	of	hiPSCs	to	
complement	animal	models	has	become	more	common	in	recent	years	(e.g.,	with	CHD7	patients	(Okuno	et	
al.	2017)),	 there	has	not	yet	been	an	effort	 to	systematically	screen	candidate	neurocristopathy	patients.	
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Although	 this	 study	 is	only	 focused	on	 two	BBS10	mutant	 lines,	our	work	clearly	 illustrates	 the	power	of	
defined	protocols	to	link	gene	variation	to	gene	function.		
BBS10	 is	 a	 ciliopathy	 gene,	 and	 is	 one	 of	 the	 most	 common	 genes	 mutated	 in	 Bardet	 Biedl	
Syndrome.	 Despite	 our	 knowledge	 of	 multiple	 BBS	 human	 disease	 variants,	 it	 has	 been	 difficult	 to	
understand	 the	 direct	 causative	 mechanisms	 underlying	 the	 human	 condition.	 An	 established	
differentiation	protocol	such	as	the	neural	crest	 induction	assay	 is	an	 important	tool	that	will	allow	us	to	
dissect	out	the	gene	variants	that	are	pathogenic.	As	the	CRISPR/Cas9	approaches	become	more	efficient,	
we	should	be	able	to	selectively	repair	the	BBS	variants	in	these	lines,	or	to	generate	“disease”	variants	in	
control	lines.	Alternatively,	over-expression	analysis	with	a	wildtype	construct	might	be	sufficient	to	rescue	
this	neural	crest	induction	phenotype,	while	overexpression	with	different	variants	would	allow	us	to	test	
specific	mutations	 for	gain-	or	 loss-of-function	during	neural	crest	 induction.	This	will	allow	us	 to	directly	
compare	 the	 effect	 of	 different	 variants	 on	 the	 same	 genetic	 background	 in	 order	 to	 help	 us	 begin	 to	
understand	the	pleiotropic	effects	seen	in	humans.		
Applications	of	an	assay	such	as	 this	one	are	also	broad.	We	can	use	this	protocol	 to	understand	
both	 the	 cellular	 and	molecular	 profiles	 of	 patient	 specific	 cells.	 For	 example,	 when	 Leung	 et	 al.	 (2016)	
initially	developed	the	short-term	protocol,	they	tested	the	requirements	of	fibroblast	growth	factor	(FGF)	
and	bone	morphogenetic	protein	 (BMP)	 signalling	during	 the	 induction	phase.	They	noted	 that	excessive	
levels	 of	 FGF	 led	 to	 increased	mesodermal	 specification,	 while	 BMP4	 supplementation	 led	 to	 increased	
non-neural	ectoderm.	In	contrast,	BMP	inhibition	reduced	the	levels	of	SOX10	positive	neural	crest	cells.	As	
BBS10	 is	 a	 key	 ciliopathy	 gene,	 and	 the	 cilium	 can	 serve	 as	 a	 node	 for	 signal	 transduction,	 it	 was	
conceivable	 that	 the	 phenotypes	 seen	 in	 our	 BBS10	 hiPSCs	 were	 due	 to	 an	 inability	 to	 respond	 to	 the	
appropriate	 inductive	cues.	As	 the	main	driver	of	 the	neural	crest	 induction	protocol	 in	 this	assay	 is	Wnt	
activation	via	GSK3	 inhibition,	our	key	finding	here	suggests	that	the	ciliopathic	hiPSCs	have	a	diminished	
ability	 to	respond	to	 the	GSK3	 inhibitor	CHIR99021,	which	 is	 included	throughout	 the	 induction	protocol.	
Indeed,	 the	 XIRY	 line	 initially	 responded	 to	 CHIR99021	 by	 upregulating	 the	 Wnt	 target	 gene	 AXIN2	
modestly;	however,	further	treatment	did	not	recapitulate	the	upregulation	seen	in	QOLG	at	120h	(Figure	
7E).	XIRY	also	fails	to	activate	expression	of	the	BMP	target	gene	MSX1.	At	this	point,	it	is	unclear	whether	
XIRY	 is	 unable	 to	 respond,	 or	 whether	 there	 is	 another	 overriding	 signal.	 In	 the	 long-term,	 a	 thorough	
molecular	analysis	such	as	RNAseq	would	be	a	more	thorough	way	to	compare	responsiveness	of	wildtype	
and	 mutant	 cells.	 Nevertheless,	 our	 findings	 provide	 an	 intriguing	 starting	 point	 for	 understanding	 the	
inductive	cues	necessary	for	neural	crest	development.	
To	 our	 knowledge,	 our	 study	 is	 a	 first	 exploration	 of	 the	 requirements	 for	 ciliopathy	 genes	 in	
human	neural	crest	development.	Our	findings	correlate	with	previous	observations	regarding	BBS	function	
in	zebrafish	models	of	neural	crest	development	(Tobin	et	al.	2008),	and	suggests	a	potential	role	for	cilia	
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genes	 during	 establishment	 of	 the	 neural	 plate	 border	 and	 induction	of	 the	 neural	 crest	 lineage.	Having	
established	this	pipeline,	these	assays	can	be	optimised	to	probe	some	key	characteristics	of	neural	crest	
cells.	For	example,	two	of	the	defining	features	of	neural	crest	cells	are	the	prodigious	migratory	capacity	
and	 the	multipotency.	Endpoint	and	 live	high-content	 imaging	assays	 can	be	developed	using	 these	 read	
outs.	 As	 we	 can	 already	 see	 from	 our	 studies,	 BBS10	 mutant	 cells	 have	 very	 different	 morphology,	
protrusive	activity	and	migratory	capacity	(data	not	shown).	In	fact,	some	ciliopathies,	including	BBS,	have	
been	 associated	 with	 Hirschsprung’s	 disease,	 which	 is	 characterised	 by	 a	 failure	 of	 migration	 in	 neural	
crest-derived	 enteric	 neurons	 (de	 Pontual	 et	 al.,	 2009).	 We	 expect	 to	 be	 able	 to	 synchronise	 our	 cell	
populations	 to	 readily	 and	 directly	 compare	 the	 cellular	 behaviours	 (as	 in	 Wiseman	 et	 al,	 2019).	 With	
regards	 to	 the	 differentiation	 capacity	 of	 neural	 crest,	 it	 should	 be	 immediately	 possible	 to	 adapt	 these	
cultures	towards	the	differentiation	of	the	diverse	cell	types	produced	by	the	neural	crest,	including	bone,	
cartilage,	adipocytes,	neurons,	pigment	and	other	cell	types.		
	
Overall,	 the	use	of	patient	derived	hiPSCs	 for	 the	modelling	of	neurocristopathic	phenotypes	can	
elucidate	 the	 requirement	 of	 specific	 genes	 at	 crucial	 points	 of	 neural	 crest	 development.	 This	 human	
genetic	 background	 specific	 approach	 in	 combination	 with	 animal	 models	 will	 lead	 to	 a	 greater	
understanding	of	mammalian	neural	crest	development	and	disease.	
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FIGURE	LEGENDS		
Figure	1.	BBS10	variant	hiPSCs	are	pluripotent	and	can	form	cilia	
A)	 Schematic	 representation	 of	 the	 primary	 cilium.	 AX	 =	 axoneme,	 BB	 =	 basal	 body,	 IFT	 =	 intraflagellar	
transport.	 BBS1-20	 proteins	 are	 depicted	 in	 their	 associated	 complex	 (BBSome	 and	 chaperonin)	 or	 by	
localisation	 to	 other	 structures.	 B)	 Schematics	 showing	 BBS10	 transcript	 and	 protein	 structure	 (723AA).	
Regions	exhibiting	homology	with	chaperonin	domains	are	shown	in	the	wildtype	protein	(scheme	adapted	
from	 (Álvarez-Satta	 et	 al.	 2017)).	 Variants	 from	 two	 BBS10	 mutant	 lines	 XIRY	 (blue)	 and	 LAIG	 (red)	 are	
mapped	onto	protein	domains	with	comparison	to	control	(QOLG	or	KEGD).		
C-E)	 Cells	 were	 immunostained	 for	 the	 pluripotency	 marker	 OCT3/4.	 Control	 (QOLG)	 cells	 and	 BBS10	
mutants	 (XIRY	and	LAIG)	all	had	positive	staining	 in	 the	nucleus.	Merge	with	DNA	dye	Hoechst	 (C’-E’).	All	
cells	exhibit	staining	although	there	is	some	variability	with	less	intense	staining	being	seen	in	the	central	
regions	of	the	colonies.		
F-H)	Staining	 for	 the	ciliary	axoneme	marker,	ARL13B	was	performed.	Control	 (KEGD)	cells	 show	positive	
staining	for	ARL13B	(F).	XIRY	cells	and	LAIG	cells	(H)	both	express	cilia.	Merge	with	DNA	dye	Hoechst	(F’–H’).	
Cilia	frequency	was	quantitated	by	manual	counting	(I).	LAIG	cells	had	a	moderate	increase	in	percentage	of	
cells	with	cilia	compared	to	control	cells.	XIRY	cells	showed	no	significant	difference	although	were	more	
variable.		P-values	were	determined	using	unpaired	Student’s	t-tests	(*	-	P=<0.05).	Scale	bars	(E’	and	H’)	=	
50um.	
Figure	2.	Neural	crest	induction	in	vivo	and	in	human	induced	pluripotent	stem	cells	
A)	In	vivo	neural	crest	induction	occurs	at	the	border	(green)	between	the	neural	plate	(blue)	and	the	non-
neural	ectoderm	(light	pink).	As	neurulation	progresses	the	neural	 folds	begin	to	approximate	and	neural	
crest	 delaminate	 from	 the	 epithelium	 and	 begin	 migration.	 B)	 In	 vitro	 neural	 crest	 induction	 in	 hiPSCs	
following	the	protocol	from	Leung	et	al.	2016.	hiPSCs	are	plated	on	Matrigel	and	treated	for	48h	in	neural	
crest	induction	(NCI)	media	plus	Rock	inhibitor	(RI).	This	is	followed	by	incubation	in	neural	crest	induction	
media	without	RI	until	120h	of	culture.	At	the	start,	pluripotency	markers	(OCT3/4,	NANOG	and	CMYC)	are	
expressed.	By	two	days	of	culture,	neural	border	markers	are	expressed	(PAX3,	PAX7,	TFAP2A,	ZIC1).	By	five	
days	of	culture,	cells	express	markers	of	neural	crest	identity	(FOXD3,	SNAIL2,	SOX10).			
Figure	3.	Neural	crest	induction	is	delayed	in	BBS10	mutant	cells.		
Phase	contrast	images	of	taken	during	neural	crest	induction	at	specified	time	points.		Control	QOLG	(A-E),	
mutant	XIRY	(F-J)	and	LAIG	(K-O)	cells.	
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Discrete	 iPSC-like	 colonies	 can	be	 seen	at	24h	 in	 all	 rows	 (B,	G	and	 L).	 In	 control	 cultures,	 cells	 are	 seen	
delaminating	 from	 colonies	 at	 48h	 (blue	 arrowhead,	 C);	 whereas	 mutant	 cultures	 start	 showing	
delamination	 at	 96h	 (blue	 arrowheads,	 I	 and	N).	 By	 120h	 there	 are	 still	 some	dense,	 colony-like	 regions	
present	in	all	cultures	(yellow	arrowheads,	E,	J	and	O.	Scale	bars	=	50µm.	
Figure	4.	Delaminated	neural	crest	cells	have	a	mesenchymal	morphology.		
Phase	 contrast	 images	 of	 differentiating	 hiPSCs	 cultures	 taken	 during	 neural	 crest	 induction	 at	 specified	
time	points.	 	Control	QOLG	(A-C),	mutant	XIRY	(D-F).	Note	that	control	QOLG	cells	at	48	hours	(A)	exhibit	
delaminated	 cells	 with	 mesenchymal	 morphology,	 in	 contrast	 to	 XIRY	 cells	 which	 do	 not	 show	 cell	
delamination	until	96	hours	(F).		Scale	bars	=	200	µm.	
Figure	5.	BBS10	mutant	cells	express	lower	levels	of	SOX10	and	P75NTR	after	neural	crest	induction.		
Immunostaining	for	the	neural	crest	markers	SOX10	(A-C)	and	P75NTR	(A’-C’).	Control	QOLG	(A)	cells	had	
high	levels	of	SOX10	and	P75NTR.	BBS10	mutant	cells	(XIRY	(B)	and	LAIG	(C))	had	significantly	lower	levels	
of	 both	 markers.	 Merge	 with	 DNA	 dye	 Hoechst	 (A’’–C’’).	 No	 positive	 staining	 was	 observed	 in	 the	 no	
primary	control	for	SOX10	or	P75NTR	(D-D’’).	Scale	bars	=	50µm.	
Figure	6.	Dynamics	of	pluripotency,	neural	plate	border	and	neural	crest	marker	expression	during	neural	
crest	induction.		
Neural	 crest	 induction	was	 carried	 out	 on	 control	 QOLG	 (blue),	mutant	 XIRY	 (purple)	 and	 LAIG	 (orange)	
hiPSC	 lines.	 Cells	 were	 harvested	 for	 RNA	 before	 plating	 (iPSC,	 time	 =	 0hrs),	 at	 48hrs	 and	 120hrs	 of	
differentiation.	 RT-qPCR	 analysis	 was	 carried	 out	 for	 pluripotency	 markers	 (CMYC	 (A),	 NANOG	 (B)	 and	
OCT3/4	(C)),	neural	border	identity	(PAX3	(D),	TFAP2A	(E)	and	PAX7	(F))	and	subsequently	markers	of	neural	
crest	identity	(FOXD3	(G),	SNAIL2	(H),	SOX10	(I)).	P-values	were	determined	using	unpaired	Student’s	t-tests	
(*	-	P=<0.05,	**	-	P=<0.001,	***	-	P=<0.0001).		
Figure	7.	BBS10	mutant	line	XIRY	is	skewed	towards	the	mesodermal	fate	and	has	diminished	WNT	and	
BMP	responsiveness.		
Neural	 crest	 induction	was	 carried	 out	 on	 control	 QOLG	 (blue),	mutant	 XIRY	 (purple)	 and	 LAIG	 (orange)	
hiPSC	 lines.	 Cells	 were	 harvested	 for	 RNA	 before	 plating	 (iPSC,	 time	 =	 0hrs),	 at	 48hrs	 and	 120hrs	 of	
differentiation.		
A-D)	RT-qPCR	analysis	 for	 a	mesodermal	marker,	BRY	 (A),	 a	 neural	marker,	SOX2	 (B),	 neural	 border/pre-
placodal	 marker,	 ZIC1	 (C)	 and	 pre-placodal	 marker	 SIX1	 (D).	 Note	 the	 increased	 levels	 of	 BRY	 (A)	 and	
decreased	levels	of	ZIC1	(C)	and	SIX1	(D)	in	XIRY.	
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E-F)	RT-qPCR	analysis	for	AXIN2	a	transcriptional	target	of	WNT	signalling	(E),	MSX1,	a	transcriptional	target	of	
BMP	signalling	 (F)	and	PTC1,	 a	 transcriptional	 target	of	Hedgehog	signalling	 (G).	 (E)	Note	 transient	 increase	 in	
AXIN2	expression	in	XIRY	from	0	hours	to	48	hours,	but	a	decrease	by	120	hours.	(F)	Note	a	failure	to	activate	
MSX1	expression	in	XIRY	and	LAIG	compared	to	control	QOLG.	(G)	Note	variability	of	PTC1	expression	in	XIRY	at	0	
hours	and	both	mutants	at	48	hours.P-values	were	determined	using	unpaired	Student’s	t-tests	(*	-	P=<0.05,	
**	-	P=<0.001,	***	-	P=<0.0001).		 	
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